Creative Biolabs has streamlined its workflow, demonstrating the effects of different technical modules in advancing actual projects
With the continuous expansion of the antibody drug market, R&D teams are facing increasingly complex resource and time pressures at multiple stages, from sequence screening to process scale-up. How to establish smoother transitions between different development stages has become a core issue of industry concern.
Recently, Creative Biolabs, drawing on its experience in antibody preparation, research-grade production, and process development, has systematically streamlined this continuous workflow, demonstrating the effects of different technical modules in advancing actual projects.
High-throughput preparation
In the early stages of drug development, researchers often evaluate multiple antibody candidate sequences simultaneously to quickly identify potentially functional molecules. Creative Biolabs’ experience shows that the high-throughput antibody production platform plays a key role in this process. The platform can process a large number of sequences in parallel within a short period, supporting various formats such as full-length IgG, scFv, Fab, etc., providing a strong data foundation that accelerates lead identification and optimisation while improving decision quality.
Non-GMP research-grade production
When a project enters the stage of mechanism research, efficacy validation, or initial process exploration, new requirements are placed on quality stability, batch consistency, and more rigorous analytical validation of antibodies. To meet this demand, Creative Biolabs’ non-GMP antibody production services are typically an important link following the high-throughput phase. The process covers the selection of expression systems, optimisation of purification methods, quality testing and multiple analytical controls, and is aimed at research purposes, emphasising process reproducibility and data reliability, laying the foundation for subsequent large-scale development.
Antibody CDMO Solutions
As research progresses to higher-level production environments, projects often transition from research-grade materials to process development, scale-up production, and even GMP systems. At this stage, Creative Biolabs’ antibody CDMO solutions, through cell line construction, process development, scale-up production, and continuous quality system management, ensure the continuity of data and process information from the early stages. For project teams, being able to form a logically continuous route between “high-throughput → non-GMP → CDMO” helps reduce the repetitive validation or resource waste caused by process fragmentation and improve time utilisation efficiency.
Creative Biolabs believes that antibody research and development are gradually shifting from “segmented execution” to “linked collaboration”. Viewing high-throughput preparation, non-GMP research-grade production, and CDMO process development as a continuous link helps project teams establish scalable development frameworks at an earlier stage, thereby achieving greater controllability and time advantages in the later stages. With the continued growth of the antibody drug innovation pipeline, this staged, highly interoperable development model is becoming a common choice for an increasing number of R&D teams.
Contributed by Creative Biolabs
